Physician profile
Mohan K Tummala
NPI 1174667109
$809.09
in general payments reported to CMS, 2019-2025
22 companies · $498 in 2025
The $498 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $44.56 · 2023: $54.22 · 2024: $212 · 2025: $498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $660 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $660.15 |
| Education | $104.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $163.31 | 2024-2025 | Xt Cdx |
| Pfizer INC. | $154.37 | 2025 | |
| Novartis Pharmaceuticals Corporation | $105.63 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $58.36 | 2025 | Opdivo, Opdualag |
| Glaxosmithkline, LLC. | $53.78 | 2025 | Ojjaara |
| Janssen Biotech, INC. | $34.18 | 2022-2024 | Tecvayli, Talvey, Darzalex |
| Astellas Pharma US INC | $31.65 | 2025 | Vyloy |
| Medtronic, INC. | $29.68 | 2023 | Osteocool Rf Ablation System |
| Array Biopharma INC | $28.80 | 2025 | Braftovi, Tukysa, Mektovi |
| Daiichi Sankyo INC. | $25.94 | 2025 | Enhertu |
| Acrotech Biopharma INC. | $25.90 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $18.75 | 2025 | Libtayo |
| Genzyme Corporation | $17.06 | 2025 | |
| Abbvie INC. | $16.08 | 2025 | |
| Celgene Corporation | $15.91 | 2025 | Breyanzi |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $15.51 | 2025 | |
| Gilead Sciences, INC. | $14.18 | 2025 | Trodelvy |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohan Tummala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.